{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:21:24Z","timestamp":1791408084573,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001529","name":"Waikato Medical Research Foundation","doi-asserted-by":"publisher","award":["188"],"award-info":[{"award-number":["188"]}],"id":[{"id":"10.13039\/501100001529","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001529","name":"Waikato Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001529","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.humpath.2014.11.012","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T16:35:34Z","timestamp":1417538134000},"page":"390-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Increased SSTR2A and SSTR3 expression in succinate dehydrogenase\u2013deficient pheochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"46","author":[{"given":"Marianne S.","family":"Elston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goswin Y.","family":"Meyer-Rochow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Conaglen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Conaglen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2014.11.012_bb0005","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2014.11.012_bb0010","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.humpath.2014.11.012_bb0015","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.humpath.2014.11.012_bb0020","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2014.11.012_bb0025","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2014.11.012_bb0030","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2265.1997.d01-1738.x","article-title":"Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma","volume":"46","author":"Kopf","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.humpath.2014.11.012_bb0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.humpath.2014.11.012_bb0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000183786","article-title":"Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors","volume":"40","author":"Invitti","year":"1993","journal-title":"Horm Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.1995.tb01877.x","article-title":"Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial","volume":"42","author":"Plouin","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.humpath.2014.11.012_bb0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0959-8049(95)00617-6","article-title":"Beneficial effects of octreotide in a patient with a metastatic paraganglioma","volume":"32A","author":"Tenenbaum","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2014.11.012_bb0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.50.507","article-title":"Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue","volume":"50","author":"Tonyukuk","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.humpath.2014.11.012_bb0065","first-page":"46","article-title":"Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies","volume":"53","author":"Koriyama","year":"2000","journal-title":"Horm Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0070","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2014.11.012_bb0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2265.2007.03124.x","article-title":"Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours","volume":"68","author":"Unger","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.humpath.2014.11.012_bb0080","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1081\/ERC-200044161","article-title":"Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors","volume":"30","author":"Unger","year":"2004","journal-title":"Endocr Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/ejh.2009.e1","article-title":"Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case","volume":"53","author":"Ruggeri","year":"2009","journal-title":"Eur J Histochem"},{"key":"10.1016\/j.humpath.2014.11.012_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/ERC-10-0175","article-title":"Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas","volume":"18","author":"Saveanu","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2014.11.012_bb0095","first-page":"1082","article-title":"In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas","volume":"74","author":"Reubi","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2014.11.012_bb0100","first-page":"1837","article-title":"Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas","volume":"80","author":"Epelbaum","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2014.11.012_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0012","article-title":"Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells","volume":"40","author":"Pasquali","year":"2008","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/jcem.84.2.5497","article-title":"Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors","volume":"84","author":"Hofland","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2014.11.012_bb0115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1055\/s-2005-921092","article-title":"Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland","volume":"37","author":"Ueberberg","year":"2005","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0120","first-page":"3483","article-title":"Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors","volume":"5","author":"Kimura","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12022-009-9098-7","article-title":"Familial cervical paragangliomas with lymph node metastasis expressing somatostatin receptor type 2A","volume":"21","author":"Kimura","year":"2010","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1196\/annals.1353.051","article-title":"Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?","volume":"1073","author":"Kolby","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.humpath.2014.11.012_bb0135","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1210\/jc.2008-1063","article-title":"Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1","volume":"93","author":"Fischer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2014.11.012_bb0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","article-title":"Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting","volume":"36","author":"K\u00f6rner","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0150","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","article-title":"Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes","volume":"41","author":"Gill","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAT.0b013e3283539932","article-title":"Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia","volume":"44","author":"Gill","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2014.11.012_bb0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.MLG.0000165806.99675.A9","article-title":"Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas?","volume":"115","author":"Duet","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.humpath.2014.11.012_bb0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2003-41355","article-title":"An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro","volume":"35","author":"Zatelli","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0170","first-page":"140051","article-title":"Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide","volume":"2014","author":"Elshafie","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.humpath.2014.11.012_bb0175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.humpath.2014.11.012_bb0180","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.humpath.2014.11.012_bb0185","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1200\/JCO.2010.31.7131","article-title":"Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas","volume":"29","author":"Cecchin","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0190","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0969-8051(00)00150-5","article-title":"[131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors","volume":"27","author":"Baulieu","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0195","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1200\/JCO.2011.36.2269","article-title":"Novel SDHD gene mutation (H102R) in a patient with metastatic cervical paraganglioma effectively treated by peptide receptor radionuclide therapy","volume":"29","author":"Poeppel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2014.11.012_bb0200","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.humpath.2014.11.012_bb0205","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771400481X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771400481X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:34:26Z","timestamp":1758645266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771400481X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S004681771400481X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2014.11.012","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase\u2013deficient pheochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2014.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}